Who Exports Pantoprazole from India — 744 Suppliers Behind a $1.3B Market
India's pantoprazole export market is supplied by 744 active exporters who collectively shipped $1.3B across 11,610 shipments. MYLAN LABORATORIES LIMITED leads with a 69.2% market share, followed by AUROBINDO PHARMA LTD and EUGIA PHARMA SPECIALITIES LIMITED. The top 5 suppliers together control 87.9% of total export value, reflecting a concentrated market structure.
Top Pantoprazole Exporters from India — Ranked by Export Value
MYLAN LABORATORIES LIMITED is the leading pantoprazole exporter from India, holding a 69.2% share of the $1.3B market across 11,610 shipments from 744 exporters. The top 5 suppliers — MYLAN LABORATORIES LIMITED, AUROBINDO PHARMA LTD, EUGIA PHARMA SPECIALITIES LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, TORRENT PHARMACEUTICALS LTD — collectively control 87.9% of total export value, indicating a highly concentrated market. Individual shares are: MYLAN LABORATORIES LIMITED (69.2%), AUROBINDO PHARMA LTD (12.5%), EUGIA PHARMA SPECIALITIES LIMITED (2.4%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (2.3%), TORRENT PHARMACEUTICALS LTD (1.5%).
Top Pantoprazole Exporters from India
Ranked by export value · 744 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | MYLAN LABORATORIES LIMITED PANTOPRAZOLE T 40 MG 100BT TAB PACKS 53001HARMLESS MEDICINES, PANTOPRAZOLE T 40 MG100BT TABMYLAN PANTOPRAZOLE T 40 MG TAB 100BT PACKS 53122 | $926.3M | 10 | 69.2% |
| 2 | AUROBINDO PHARMA LTD PANTOPRAZOLE TABLETS 40MG(PANTOPRAZOL PUPANTOPRAZOLE TABLETS 20MG(PANTOPRAZOL AUPANTOPRAZOLE TABLETS 40MG(PANTOPRAZOL AU | $167.6M | 13 | 12.5% |
| 3 | EUGIA PHARMA SPECIALITIES LIMITED PANTOPRAZOLE TABLETS 40MG(PANTOPRAZOL PUPANTOPRAZOLE TABLETS 20MG(PANTOPRAZOL AUPANTOPRAZOLE TABLETS 40MG(PANTOPRAZOL AU | $32.4M | 3 | 2.4% |
| 4 | SUN PHARMACEUTICAL INDUSTRIES LIMITED COMBIPACK OF PANTOPRAZOLE FOR INJECTIONPANTOPRAZOLE SODIUM DELAYED-RELEASE TABLPANTOPRAZOLE GASTRO-RESISTANT TABLETS 20MG 4X7S | $31.0M | 19 | 2.3% |
| 5 | TORRENT PHARMACEUTICALS LTD PANTOPRAZOLE TABLETS 40MG(PANTOPRAZOL PUPANTOPRAZOLE TABLETS 20MG(PANTOPRAZOL AUPANTOPRAZOLE TABLETS 40MG(PANTOPRAZOL AU | $19.7M | 23 | 1.5% |
| 6 | IPCA LABORATORIES LIMITED COMBIPACK OF PANTOPRAZOLE FOR INJECTIONPANTOPRAZOLE T 40 MG 100BT TAB PACKS 53001HARMLESS MEDICINES, PANTOPRAZOLE T 40 MG100BT TAB | $16.2M | 13 | 1.2% |
| 7 | LINCOLN PHARMACEUTICALS LTD COMBIPACK OF PANTOPRAZOLE FOR INJECTIONPANTOPRAZOLE SODIUM DELAYED-RELEASE TABLPANTOPRAZOLE AND DOMPERIDONE TABLETS (PA | $16.0M | 13 | 1.2% |
| 8 | AUROBINDO PHARMA LIMITED PANTOPRAZOLE TABLETS 40MG(PANTOPRAZOL PUPANTOPRAZOLE TABLETS 20MG(PANTOPRAZOL AUPANTOPRAZOLE TABLETS 40MG(PANTOPRAZOL AU | $11.8M | 8 | 0.9% |
| 9 | CIPLA LIMITED PANTOSEC 40 TABLETSPANTOPRAZOLE SODIUM DELAYED-RELEASE TABLPANTOVENT-D (PANTOPRAZOLE & DOMPERIDONE | $8.6M | 5 | 0.6% |
| 10 | MACLEODS PHARMACEUTICALS LTD PANTOPRAZOLE AND DOMPERIDONE TABLETS (PAPANTOPRAZOLE GASTRO-RESISTANT TABLETS 20MG 4X7SPANTORAZ INJECTION (PANTOPRAZOLE FOR INJ | $7.3M | 11 | 0.5% |
| 11 | TORRENT PHARMACEUTICALS LIMITED PANTOPRAZOLE TABLETS 40MG(PANTOPRAZOL PUPANTOPRAZOLE TABLETS 20MG(PANTOPRAZOL AUPANTOPRAZOLE TABLETS 40MG(PANTOPRAZOL AU | $6.3M | 17 | 0.5% |
| 12 | MICRO LABS LIMITED PANTOPRAZOLE TABLETS 40MG(PANTOPRAZOL PUPANTOPRAZOLE TABLETS 20MG(PANTOPRAZOL AUPANTOPRAZOLE TABLETS 40MG(PANTOPRAZOL AU | $5.6M | 19 | 0.4% |
| 13 | AMNEAL PHARMACEUTICALS PRIVATE LIMITED PANTOPRAZOLE SODIUM DELAYED-RELEASE TABL | $4.2M | 1 | 0.3% |
| 14 | INNOVA CAPTAB LIMITED PANTOSEC 40 TABLETSPANTOVENT-D (PANTOPRAZOLE & DOMPERIDONEPANTOPRAZOLE AND DOMPERIDONE TABLETS (PA | $3.9M | 6 | 0.3% |
| 15 | DR.REDDY'S LABORATORIES LTD PANTOPRAZOLE T 40 MG 100BT TAB PACKS 53001HARMLESS MEDICINES, PANTOPRAZOLE T 40 MG100BT TABMYLAN PANTOPRAZOLE T 40 MG TAB 100BT PACKS 53122 | $3.7M | 6 | 0.3% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Pantoprazole exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Aurobindo Pharma Limited | Approved | Yes | Yes | 164 | Received FDA approval for Vancomycin Hydrochloride for Injection in August 2023. |
| Eugia Pharma Specialities Limited | Approved | Yes | Yes | 164 | Wholly owned subsidiary of Aurobindo Pharma; received FDA approval for Vancomyci |
| Mylan Laboratories Limited | Approved | Yes | Yes | Multiple | Merged with Upjohn to form Viatris in November 2020. |
| Sun Pharmaceutical Industries Limited | Approved | Yes | Yes | Multiple | Received FDA approval for multiple generic drugs; details available on FDA websi |
| Torrent Pharmaceuticals Limited | Approved | Yes | Yes | Multiple | Received Establishment Inspection Report from US FDA for Dahej facility in 2023. |
| Lincoln Pharmaceuticals Limited | Not Listed | Yes | Yes | Not Listed | Received EU GMP certification for Khatraj facility in May 2020. |
| Cipla Limited | Approved | Yes | Yes | Multiple | Received FDA approval for multiple generic drugs; details available on FDA websi |
| Dr. Reddy's Laboratories Ltd | Approved | Yes | Yes | Multiple | Received FDA approval for multiple generic drugs; details available on FDA websi |
TransData Nexus reviewed the regulatory standing of 8 leading Pantoprazole exporters from India. 7 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 8 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Pantoprazole sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for the production of Active Pharmaceutical Ingredients (APIs). Companies like Mylan Laboratories Limited, which accounts for 69.2% of Pantoprazole exports, have significant operations in this region. The city's infrastructure supports large-scale API manufacturing, ensuring a steady supply of high-quality raw materials essential for Pantoprazole production.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara belt in Gujarat is renowned for its expertise in pharmaceutical formulations. Aurobindo Pharma Ltd., contributing 12.5% to Pantoprazole exports, has a notable presence here. This cluster excels in converting APIs into finished dosage forms, leveraging advanced manufacturing facilities and a skilled workforce to produce Pantoprazole tablets and injectables that meet international quality standards.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad region serves as a critical export gateway for pharmaceutical products. Companies such as Sun Pharmaceutical Industries Limited, responsible for 2.3% of Pantoprazole exports, operate extensively in this area. Proximity to major ports facilitates efficient global distribution, particularly to key markets like the United States, which receives 68.3% of India's Pantoprazole exports.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh is a prominent pharmaceutical manufacturing zone, offering tax incentives that attract numerous companies. While specific data on Pantoprazole production in this cluster is limited, the region's favorable policies and established infrastructure make it a viable location for cost-effective manufacturing of various pharmaceutical products.
5Sourcing Recommendations
- Diversify Supplier Base: While Mylan Laboratories Limited dominates Pantoprazole exports, consider engaging with other significant suppliers like Aurobindo Pharma Ltd. and Sun Pharmaceutical Industries Limited to mitigate supply chain risks.
- Leverage Regional Strengths: Utilize Hyderabad's API production capabilities and Ahmedabad-Vadodara's formulation expertise to ensure a seamless supply chain from raw material to finished product.
- Optimize Logistics: Capitalize on the Mumbai-Thane-Raigad region's export infrastructure to facilitate efficient distribution to international markets, especially the United States.
- Evaluate Cost Benefits: Assess the financial advantages of manufacturing in tax incentive zones like Baddi-Nalagarh to potentially reduce production costs without compromising quality.
By strategically engaging with these pharmaceutical clusters, companies can enhance the efficiency and reliability of their Pantoprazole supply chain.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Pantoprazole exporters from India
Sun Pharmaceutical Industries Limited — Sun Pharma acquires remaining stake in Taro Pharmaceuticals
Sun Pharma entered into a definitive merger agreement to acquire all outstanding shares of Taro Pharmaceuticals for $347.73 million, consolidating its ownership. - IMPACT: This acquisition is expected to enhance Sun Pharma's product portfolio, potentially increasing Pantoprazole exports.
Impact: This acquisition is expected to enhance Sun Pharma's product portfolio, potentially increasing Pantoprazole exports.
Sun Pharmaceutical Industries Limited — Sun Pharma acquires Checkpoint Therapeutics for $355 million
Sun Pharma acquired Checkpoint Therapeutics, a company specializing in immunotherapy and targeted oncology treatments, for $355 million. - IMPACT: This acquisition may diversify Sun Pharma's product offerings, with potential implications for Pantoprazole export strategies.
Impact: This acquisition may diversify Sun Pharma's product offerings, with potential implications for Pantoprazole export strategies.
Sun Pharmaceutical Industries Limited — Sun Pharma addresses counterfeit drug allegations
Sun Pharma investigated and confirmed that certain drug batches flagged by the CDSCO as "not of standard quality" were counterfeit and not manufactured by them. - IMPACT: By addressing counterfeit concerns, Sun Pharma aims to maintain trust in its products, potentially stabilizing Pantoprazole export volumes.
Impact: By addressing counterfeit concerns, Sun Pharma aims to maintain trust in its products, potentially stabilizing Pantoprazole export volumes.
Common Questions — Pantoprazole Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which pantoprazole supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, MYLAN LABORATORIES LIMITED leads with 661 recorded shipments worth $926.3M. AUROBINDO PHARMA LTD (1,356 shipments) and EUGIA PHARMA SPECIALITIES LIMITED (308 shipments) are also established high-volume exporters.
Q How many pantoprazole manufacturers are there in India?
India has 744 active pantoprazole exporters with a combined export market of $1.3B across 11,610 shipments to 154 countries. The top 5 suppliers hold 87.9% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for pantoprazole from India?
Average FOB unit price: $3.77 per unit, ranging from $0.00 to $4449.94. Average shipment value: $115.3K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 744 verified Indian exporters of Pantoprazole ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 11,610 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 154 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
11,610 Verified Shipments
744 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists